ሐምሌ 2022: በ Emergen Research በተካሄደው በጣም የቅርብ ጊዜ ምርምር መሠረት ፣ የ CAR ቲ-ሴሎች ሕክምና ዓለም አቀፍ ገበያ በ 1.29 2021 ቢሊዮን ዶላር ደርሷል እና በትንበያው ጊዜ ውስጥ የ 24.9 በመቶ CAGR ገቢ ያስመዘግባል። በዓለም ዙሪያ እየጨመረ ያለው የካንሰር በሽታ እና በካንሰር ምክንያት እየጨመረ ያለው የሞት መጠን በአለም አቀፍ የ CAR-T ሕዋስ ሕክምና ገበያ ውስጥ ትንበያው ወቅት የገቢ እድገት ዋና ነጂዎች ይሆናሉ ተብሎ ይጠበቃል ። የክሊኒካዊ ሙከራ እንቅስቃሴዎችን በብሬክ ፍጥነት መስፋፋት፣ የውህደት እና ግዢዎች መስፋፋት እና የመጀመርያ የህዝብ አቅርቦቶች ማራኪነት ለአለም አቀፍ የCAR ቲ-ሴል ቴራፒ ገበያ የገቢ እድገት አስተዋጽኦ የሚያደርጉ ነገሮች ናቸው።
The primary objective of the report is to provide an overview of the market, including product scope, growth prospects, and potential risks. In-depth information about each participant in the global የ CAR ቲ-ሴል ቴራፒ market, including that participant’s global standing, financial status, product launch, and business expansion plans, is included in the report. The participants in the market are concentrating their efforts on the creation of a variety of strategies, including partnerships, mergers and acquisitions, joint ventures, product launches, and investments in research and development.
According to the findings of the study, there are certain types of dangers and difficulties that can serve as an obstacle for a company. Granularity can be added to the overall research by performing an in-depth analysis of the የ CAR ቲ-ሴል ቴራፒ market in the context of various aspects of the larger environment, such as the social, political, economic, and technological settings. In addition, the study generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects to demonstrate how going forward the company will see a significant upswing in its performance.
ከሪፖርቱ ተጨማሪ ጉልህ ግኝቶች ያመለክታሉ
In 2021, the segment of diffuse large B-cell ሊምፎማ was responsible for the majority of the rapid revenue share. A cancer of the lymphatic system, which is an essential component of the immune system, called diffuse large B-cell lymphoma has a rapid growth rate. It has an effect on the blood cells that generate antibodies, which are used to fight infections. In certain instances, DLBCL can be cured. The majority of patients suffering from DLBCL have a favourable response to initial treatments such as chemotherapy. In the case of some people, the illness either becomes resistant to treatment, which means that it no longer responds to it, or it relapses, which means that it returns after treatment has been completed. These patients may be candidates for treatment with ኪሜሪክ አንቲጂን ተቀባይ ቲ-ሴል ሕክምና, which utilises the patient’s own immune cells in the fight against DLBCL. T-cells are taken out of the patient’s blood, modified in the laboratory with so-called chimeric antigen receptors that help in recognising and destroying cancer cells, and then reintroduced into the patient’s blood again. This process is repeated several times.
In 2021, the hospital segment was responsible for a fair amount of the total revenue. The CAR T-cell therapy will reprogramme the patient’s T-cells so that they will target the antigens produced by the tumour. CAR T-cell therapy has shown full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia, and it has shown a full remission rate of 40 percent in patients with symptomatic B-cell ሆጅኪን ያልሆኑ ሊምፎማዎች who have failed several prior lines of therapy. Both of these patient populations have B-cell acute lymphoblastic leukaemia.
በአሁኑ ጊዜ በገበያ ውስጥ እየሰሩ ያሉት ዋና ዋና ኩባንያዎች በዚህ ሪፖርት ውስጥ ተጨማሪ ምርመራ ይደረግባቸዋል, የኩባንያዎቻቸው መገለጫዎች, የምርት ፖርትፎሊዮዎች, የማስፋፊያ ስልቶች እና ስትራቴጂካዊ ጥምረት ናቸው. የእነዚህ አይነት ጥምረት ምሳሌዎች ውህደት እና ግዢ፣ ትብብር እና የጋራ ስራን ያካትታሉ። ከዚህ በተጨማሪ የኩባንያውን ስኬቶች እና የፋይናንስ ደረጃዎች እንዲሁም የገበያ ተደራሽነትን እና የኩባንያውን ዓለም አቀፋዊ አቋም በተመለከተ ድምቀቶችን ያቀርባል.
በአለምአቀፍ የCAR ቲ-ሴል ቴራፒ ገበያ ውስጥ የተገለጹ ኩባንያዎች፡-
Novartis AG፣ Pfizer Inc.፣ CARsgen Therapeutics Co., Ltd .
ስለ ዓለም አቀፉ CAR T-cell Therapy ገበያ ዘገባ በሚከተሉት ላይ ያንብቡ፡- https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
